Live Chat

CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74,2% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Vir Biotechnology VIR

VirBiotechnology realtidsdiagram

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Tommy Yap 2025 Feb 22, 16:00

Week Ahead: Australia Inflation and US Core PCE Price Index in Focus

Forex Indices
Why did stock market drop today due to Walmart's economic outlook.
Vanessa L 2025 Feb 21, 06:40

Why Did Stock Market Drop Today? Walmart’s Forecast Sparks Economic Concerns

Frances Wang 2025 Feb 20, 16:00

Shiba inu news: What is happening to Shiba Inu today?

Cryptocurrencies
Alvaro Ramos 2025 Feb 20, 16:00

Dow jones stock markets today: Dow falls 450 points

Indices
Frances Wang 2025 Feb 20, 16:00

Lucid stock news today: Is Lucid stock expected to go up?

Stocks
Frances Wang 2025 Feb 20, 16:00

Forex market update: US Dollar struggles on mixed data

Forex
Tommy Yap 2025 Feb 20, 16:00

Morning Note: Oil Prices Climb, UK Retail Sales Rise & U.S. PMI

Morning Note Oil
Space.Xia 2025 Feb 20, 16:00

Asian Markets Stagnate on Trade Fears; Alibaba Drives HK Surge

Info

Spread

0.07

Spread (%)

0.7330 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Måndag

14:31 - 20:59

Tisdag

14:31-20:59

Onsdag

14:31-20:59

Torsdag

14:31-20:59

Fredag

14:31-20:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

1317980416

Utelöpande aktier

137720000

Rapportdatum (nästa)

0000-00-00

Utd-procent

Datum efter utdelning

Förväntad framtida årlig utdelningsprocent

0

Förväntad framtida årlig direktavkastning

0

Vinst per aktie

-3.93

Läs mer om detta instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)
Relaterade instrument
Trustpilot
Live Chat